<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01442428</url>
  </required_header>
  <id_info>
    <org_study_id>WS967180</org_study_id>
    <nct_id>NCT01442428</nct_id>
  </id_info>
  <brief_title>Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial</brief_title>
  <official_title>Randomized Controlled Trial for Corticosteroids Versus NSAIDs With or Without Adjunctive Atorvastatin for the Treatment for Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Minnesota Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberculosis is the most common opportunistic infection (OI) in HIV-infected persons&#xD;
      worldwide, including in South East Asia. Significant numbers of patients experience&#xD;
      tuberculosis-related paradoxical immune reconstitution inflammatory syndrome (TB-IRIS) after&#xD;
      ART initiation, yet the optimal treatment of TB-IRIS is unknown. A recent&#xD;
      randomized-controlled trial showed the benefit of prednisone over placebo in reduction of&#xD;
      days of hospitalization and invasive procedures. The investigators hypothesize that&#xD;
      nonsteroidal anti-inflammatory drugs (NSAIDs) are as effective as corticosteroids for&#xD;
      treatment of non-life threatening TB-IRIS in HIV-infected patients and hypothesize that&#xD;
      adjunctive treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase&#xD;
      inhibitors (Statins) may improve the outcomes. This is a randomized controlled trial with a&#xD;
      2x2 factorial design to test the relative benefit of corticosteroids, NSAIDS, and Statins for&#xD;
      the symptomatic and immunologic control of TB-IRIS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    2011 Thailand flooding led to loss of GMP pharmacy, project delays, and further regulatory&#xD;
    challenges.&#xD;
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Clinical Symptom Score at Day 7, as measured by the 10-point visual analog scale to quantify symptom severity.</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum C-reactive protein at Day 7</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days of hospitalization combined with outpatient therapeutic procedures</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study medicine discontinuation</measure>
    <time_frame>28 days</time_frame>
    <description>(e.g. switching to open-label medication)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky Performance Status Scale at day 7 and 28;</measure>
    <time_frame>Day 7 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>56 days</time_frame>
    <description>DAIDS Grading Scale 3-5 events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiologic improvement at 2 weeks;</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 count change</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of IRIS manifestations within the 8 week study period</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ART or TB therapy discontinuation</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of sputum acid fast bacilli (AFB) smear positivity at day 28</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Immune Reconstitution Inflammatory Syndrome</condition>
  <condition>Immune Reconstitution Syndrome</condition>
  <condition>Tuberculosis</condition>
  <condition>HIV-infection/Aids</condition>
  <arm_group>
    <arm_group_label>Steroid+Statin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;&#xD;
Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSAID+Statin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;&#xD;
Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid+Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;&#xD;
Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSAID+Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;&#xD;
Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week</description>
    <arm_group_label>Steroid+Placebo</arm_group_label>
    <arm_group_label>Steroid+Statin</arm_group_label>
    <other_name>decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration in this TB population)</description>
    <arm_group_label>NSAID+Statin</arm_group_label>
    <arm_group_label>Steroid+Statin</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week</description>
    <arm_group_label>NSAID+Placebo</arm_group_label>
    <arm_group_label>NSAID+Statin</arm_group_label>
    <other_name>naproxen sodium</other_name>
    <other_name>Aleve</other_name>
    <other_name>Anaprox</other_name>
    <other_name>Antalgin</other_name>
    <other_name>Feminax Ultra</other_name>
    <other_name>Flanax</other_name>
    <other_name>Inza</other_name>
    <other_name>Midol Extended Relief</other_name>
    <other_name>Nalgesin</other_name>
    <other_name>Naposin</other_name>
    <other_name>Naprelan</other_name>
    <other_name>Naprogesic</other_name>
    <other_name>Naprosyn</other_name>
    <other_name>Narocin</other_name>
    <other_name>Proxen</other_name>
    <other_name>Synflex</other_name>
    <other_name>Xenobid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Atorvastatin placebo</description>
    <arm_group_label>NSAID+Placebo</arm_group_label>
    <arm_group_label>Steroid+Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1 infection documented by any locally licensed ELISA or rapid HIV test kit.&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Paradoxical TB-IRIS diagnosed by case definition (see section 5.2)&#xD;
&#xD;
          -  Ability and willingness of the participant or legal guardian/representative to give&#xD;
             informed consent. Receiving appropriate ART and anti-TB therapy, as judged by the site&#xD;
             investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to take oral medication;&#xD;
&#xD;
          -  Receiving chemotherapy, immunosuppressant, corticosteroid, NSAID, or statin&#xD;
             medications; (ASA is acceptable)&#xD;
&#xD;
          -  Cannot or unlikely to attend regular clinic visits;&#xD;
&#xD;
          -  Known allergy to NSAIDs, statins or corticosteroids;&#xD;
&#xD;
          -  Liver transaminase &gt; 2 times the upper limit of normal within 60 days of enrollment;&#xD;
&#xD;
          -  History of myositis/myopathy;&#xD;
&#xD;
          -  High Investigator Suspicion of anti-TB treatment failure due to TB-resistance or&#xD;
             medication non-adherence;&#xD;
&#xD;
          -  Receiving ongoing azole anti-fungal for treatment or secondary prophylaxis of&#xD;
             cryptococcosis, histoplasmosis or penicilliosis;&#xD;
&#xD;
          -  Serious co-morbidities, co-infections, or laboratory values who should not receive&#xD;
             NSAIDs, steroid or statins, as judged by the site investigator;&#xD;
&#xD;
          -  Minimal IRIS reaction which is unlikely to require treatment, as judged by the site&#xD;
             investigator;&#xD;
&#xD;
          -  Pregnancy (a negative urine pregnancy test at screening is required for women of&#xD;
             childbearing potential) or breast feeding;&#xD;
&#xD;
          -  Receiving a HIV treatment regimen containing a protease inhibitor at study entry.&#xD;
&#xD;
        Exclusion for Randomization A Only&#xD;
&#xD;
          -  Life threatening TB-IRIS, as defined by:&#xD;
&#xD;
          -  Acute respiratory failure; PaO2 &lt; 60 on room air or;&#xD;
&#xD;
          -  Altered mental status or;&#xD;
&#xD;
          -  New focal neurological deficit or;&#xD;
&#xD;
          -  Compression of the vital organs.&#xD;
&#xD;
          -  Persons with uncontrolled diabetes mellitus;&#xD;
&#xD;
          -  Impair kidney function, glomerular filtration rate &lt;60 ml/min; within 72 hours of&#xD;
             consent&#xD;
&#xD;
          -  Uncontrolled congestive heart failure&#xD;
&#xD;
          -  History of bleeding disorder;&#xD;
&#xD;
          -  Platelet count &lt;100,000/µL;&#xD;
&#xD;
          -  History of significant gastrointestinal bleeding or ulceration;&#xD;
&#xD;
          -  Prior adjunctive corticosteroid therapy for this TB episode for &gt; 48 hr;&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sasisopin Kiertiburanakul, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David R Boulware, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ubonvan Jongwutiwes, MD</last_name>
    <role>Study Director</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Mai University</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bamrasnaradura Infectious Diseases Institute</name>
      <address>
        <city>Nonthaburi</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>August 30, 2011</study_first_submitted>
  <study_first_submitted_qc>September 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2011</study_first_posted>
  <last_update_submitted>November 20, 2013</last_update_submitted>
  <last_update_submitted_qc>November 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TB</keyword>
  <keyword>AIDS</keyword>
  <keyword>HIV</keyword>
  <keyword>IRIS</keyword>
  <keyword>immune reconstitution inflammatory syndrome</keyword>
  <keyword>anti-inflammatory</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Immune Reconstitution Inflammatory Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

